Greg Tolpigin has published positive commentary about the future of Orthocell, and the potential for our CelGroâ„¢ product in this article on Sharecafe.Â
Orthocell receives patent for breakthrough CelGro ‘collagen rope’ to treat ACL injuries
Small Caps has reported on Orthocell’s recent patent announcement for our breakthrough CelGro collagen rope device to enhance the surgical repair of anterior cruciate ligament (ACL) injuries.
Australia’s Orthocell ready to file on interim Celgro™ data
BioWorld has reported on Orthocell’s plans to seek early FDA approval for our Celgroâ„¢ nerve regeneration treatment, following positive interim clinical results in quadriplegic patients.
Orthocell on course to revolutionise nerve regeneration after positive interim clinical results
Orthocell has been featured in Small Caps following positive interim clinical results for CelGroâ„¢, a collagen medical device that facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications.
Orthocell shares boosted by nerve repair trial success
Journalist Sarah Jane Tasker, from The Australian, discusses the positive results from Orthocell’s clinical trial of nerve repair product, CelGroâ„¢, in quadriplegic patients.
Orthocell reports high success rate from CelGro surgical trial on patients with rotator cuff injuries
Small Caps has reported on the follow-up results from our CelGroâ„¢ tendon regeneration clinical trial, confirming all patients with rotator cuff injuries achieved a successful tendon repair with no need for revision surgeries.
Orthocell’s latest pre-clinical study underlines CelGro™ performance in nerve repair
Orthocell’s pre-clinical results for the use of CelGroâ„¢ in enhancing the repair of severed peripheral nerves have been featured in Small Caps.Â
Orthocell’s CelGro bone regeneration device accelerates dental implant treatment timeframes, cuts costs
Small Caps has featured the outcomes of Orthocell’s single-stage dental implant study, evaluating treatment with our CelGroâ„¢ collagen membrane.Â
Bell Potter launches placement for Orthocell
Orthcell’s planned equity raise has been featured in AFR’s Street Talk.
Orthocell shares spike 350% following interim results of Celgro nerve regeneration study
Orthocell CEO Paul Anderson spoke to BioWorld Asia about the interim results of our nerve regeneration trial, that saw patients regain sensation and muscle function following Celgroâ„¢ nerve regeneration treatment.